


KS
201
067
21 594
1419
1986

The
24th International Symposium on
Controlled Release of  Bioactive Materials

Stockholm, Sweden June 15-19, 1997

STOCKHOLMSMÄSSAN

CRS Controlled Release Society, Inc.

An international society advancing the science and technology of chemical and biological delivery systems.

PROCEEDINGS

19
97



STOCKHOLM

Symposium: June 16 - 19, 1997

Exhibit: June 17 - 19, 1997

STOCKHOLMSMÄSSAN
Stockholm International Fairs

Workshops:

June 15, 1997
Sheraton Hotel and
Grand Hotel

June 16, 1997
STOCKHOLMSMÄSSAN
Stockholm International Fairs

Published by the
Controlled Release Society, Inc.

Proceed. Int'l. Symp. Control.
Rel. Bioact. Mater., 24 (1997)
ISSN 1022-0178

Program Chairs:

Karl-Erik Falk
Asten Hässle AB, USA

Teruo Okano
Tokyo Women's Medical College, Japan

ished by

Controlled Release Society, Inc.
Milwaukee Avenue
335
Eldredge, IL 60015 USA

dition, 1997

ight© 1997 by The Controlled Release Society, Inc.

rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher.

1022-0178

Printed in the USA

Abstracts in this book are listed in the following:

Biochemical Scientific Abstracts
Chemical Abstracts
Engineering Abstracts
Environmental Abstracts
Medical Abstracts
Pharmaceutical Abstracts
Physical Abstracts
Public Health Abstracts
Transportation Abstracts

Controlled Release Society assumes no responsibility for abstracts not available at time of printing.

1997 Symposium and Workshop Scientific Program Committee

1997 Cochairs

Karl-Erik Folk, Astra Hälsjö AB, USA
Teruo Okano, Tokyo Women's Medical College, Japan

1996 Chair

Vincent H. L. Lee, University of Southern California, USA

1998 Cochairs

Kenneth Park, Purdue University, USA
Russell O. Potts, Cygnus, USA

Committee

Maria Alonso, University de Santiago de Compostela, Spain

Ursula Hultquist Bengtsson, Astra Draco AB, Sweden

Martin Davies, University of Nottingham, England, UK

Bath Duncan, University of London, England, UK

Sven Engström, Lund University, Sweden

Tom Ferguson, Eli Lilly, USA

Sylvan Frank, Ohio State University, USA

Ezeriah Golomb, Hebrew University of Jerusalem, Israel

Jindřich Kopeček, University of Utah, USA

Farka Kopečková, University of Utah, USA

Claus-Michael Lehr, University of Saarland, Germany

Hans Lennernäs, Uppsala University, Sweden

Robert Levy, University of Michigan, USA

Mary Marshall, Southwest Research Inst., USA

Terry Mazer, Abbott Laboratories, USA

Colin Melia, University of Nottingham, England, UK

Derek O'Hagan, Chiron Corporation, USA

Judy Reese, Monsanto, USA

Yutichi Sugiyama, University of Tokyo, Japan

Victor Yang, University of Michigan, USA

1996-1997 Officers of the Controlled Release Society, Inc.

President

Tsunefji Nagai
Hoshi University
Tokyo, Japan

Past President

Jiřdřich Kopeček
University of Utah
Salt Lake City, UT
USA

President Elect

Ronald A. Siegel
University of California
San Francisco, CA
USA

Vice President

Thomas Kissel
Philipps-University of Marburg
Marburg, Germany

Scientific Secretary

Robert Gurny
University of Geneva
Geneva, Switzerland

Treasurer

Lisa Brammon-Peppas
Biogel Technology, Inc.
Indianapolis, IN
USA

Administrative Staff of the Controlled Release Society, Inc.

Executive Director

M. Judith Roseman
CRS Administrative Headquarters
1020 Milwaukee Ave., Suite 333
Deerfield, IL 60015 USA
Phone: (847) 808-7071
Fax: (847) 808-7073
E-mail: crs@crsadmhdq.org
WWW: <http://www.crsadmhdq.org/>

European Manager

Daphne L. Romy
School of Pharmacy
University of Geneva
30, quai E. Ansermet
CH-1211 Geneva 4 Switzerland
Phone/Fax: (+41) 22 703 6339
E-mail: Daphne.Romy@pharm.unige.ch

Financial Manager

Robert C. Koestler
College Station, TX USA

Board of Governors

Maria Jos Alonso	Terno Okano
Simon Benita	Kathleen Boskos
Helle Brundsted	Hans Schreier
Susan Cady	Robert Sparks
Jonathan Hadgraft	Yuichi Sugiyama
Mitsuru Hashida	Vladimir P. Torchilin
Scott Herbig	Glynn Wilson
Jean-Paul Marty	

Table of Contents

BY SESSION NAME	Page #	Paper #
Podium Presentations	3-224	201-414
<i>Tuesday, June 17, 1997</i>	3-119	201-261
Oral Drug Delivery	3-18	201-208
Transdermal and Iontophoretic Delivery	19-32	209-215
Delivery of Genes and Oligonucleotides	33-48	216-223
New Materials & Principles and Techniques for Drug Delivery I	49-64	224-232
Pulmonary and Alveolar Drug Delivery	65-80	233-240
Drug Targeting	81-98	241-249
Minisymposium on Innovative Aspects of Controlled Drug Release --- Sponsored by the CRS and Capsugel	99-112	250-256
Minisymposium on Delivery Strategies for Mucosal Immunization	113-119	257-261
<i>Wednesday, June 18, 1997</i>	120-197	301-340
New Materials & Principles and Techniques for Drug Delivery II	120-135	301-308
Agricultural and Veterinary Applications of Controlled Release	136-150	309-316
Minisymposium on Targetable Drug Carriers for Drug Delivery	151-160	317-321
New Materials & Principles and Techniques for Drug Delivery III	161-178	322-330
Transmucosal Delivery	179-186	331-334
Minisymposium on Restenosis and Local Drug Delivery Strategies	187-197	335-340
<i>Thursday, June 19, 1997</i>	198-224	401-414
Themed Session: Beyond Liposomes...Lipids as Components in Drug Delivery Systems	198-207	401-405
Themed Session: Sustainable Agriculture--- Low Use Rate Agrochemicals	208-214	406-409
Minisymposium on Drug Delivery to the Brain	215-224	410-414
Posters	225-1053	5001-6587
<i>Posters I</i>	225-640	5001-5299
Oral Drug Delivery	225-406	5001-5094
Transmucosal Delivery	407-440	5101-5117
New Materials & Principles and Techniques for Drug Delivery	441-640	5200-5299
<i>Posters II</i>	641-1052	6001-6587
Delivery of Genes and Oligonucleotides	641-694	6001-6022
Transdermal and Iontophoretic Delivery	685-724	6101-6120
Agricultural and Veterinary Applications of Controlled Release	725-744	6201-6211
Pulmonary and Alveolar Drug Delivery	745-748	6301-6302
Drug Targeting	749-880	6401-6466
New Materials & Principles and Techniques for Drug Delivery	881-1052	6501-6587
Key Words	1053-1056	
Author Index	1057-1073	

purpose of validating the theoretical approach. The expected peak location and width of the bolus (introduced 10 cm into the duodenum) is indicated in the figure. The peak of the bolus is exactly 10 cm beyond the distance \bar{U}^*t from the entrance to the duodenum, reflecting the fact that the bolus was introduced 10 cm into the small intestine. Also, the width of the peak corresponds to the theoretical expectation ($\sqrt{D^*t}$).

Theoretical serum concentrations were compared with experimental data in various cases. Figure 2 shows a comparison between experimental data and theoretical predictions for the case of ibuprofen, administered orally in humans (5). Total predicted absorption is 51%, near the experimental estimate. The good match of the data is obtained upon assuming an epithelial permeability of 7.8×10^{-6} cm/s.




Fig. 2 Comparison of experimental (symbol) and predicted (solid curve) serum concentration profiles for ibuprofen following oral administration to humans.

Figure 3 shows a comparison between experimental data and theoretical predictions for the case of GHRP-1, administered orally in humans (6). Theoretical absolute bioavailability is approximately 0.1%. The theoretical

prediction is obtained upon assuming an epithelial permeability of 6×10^{-7} cm/s.




Fig. 3 Comparison of experimental (symbol) and predicted (solid curve) serum concentration profiles for GHRP-1 following oral administration to humans.

The proposed theoretical model can be used to predict the absorbed systemic concentrations of therapeutics ranging from small lipophilic molecules to macromolecules.

REFERENCES

1. Kreydiyyeh, S.I., Bitar, K.M., Bikhazi, A.B. *J. Pharm. Sci.*, 79, 494 (1990).
2. Adson, A., Raab, T.J., Burton, P.S., Barsuhn, C.L., Hilgers, A.R., Audus, K.L., Ho, N.F. *J. Pharm. Sci.*, 83, 1529 (1994).
3. Brenner, H., Edwards, D.A. *Macrotransport Processes*. Boston: Butterworth-Heinemann (1993).
4. Stoll, B., Batycky, R., Leipold, H., Milstein, S., Edwards, D. Submitted (1997).
5. Dressman, J.B., Bass, P., Ritschel, W.A., Friend, D.R., Rubinstein, A., Ziv, E. *J. Pharm. Sci.*, 82, 857 (1993).
6. Bowers, C.Y. *J. Ped. Endocrin.* 6, 21 (1993).

WATER SOLUBLE FILM FOR ORAL ADMINISTRATION

Jian-Hwa Guo¹ and Horst Zerbe²

¹Aqualon Division, Hercules Inc., 500 Hercules Rd., Wilmington, DE 19808-1599
²LTS Corp., 21 Henderson Dr., West Caldwell, NJ 07096

Introduction

Mucoadhesive dosage forms for application to the oral cavity which are designed to deliver therapeutic and/or cosmetic agents to the oral mucosa are known in the art. Sanvorderke and Leung (1) described a mucoadhesive carrier allowing the controlled release of a therapeutic agent via the mucosal tissue comprising an anhydrous but hydratable polymer matrix and amorphous fumed silica. An optional water-insoluble film can be added to provide a non-adhering surface. They also disclosed a trilaminar film suitable for prolonged delivery of an active ingredient in the oral cavity (2). In a similar way, Mizobuchi, et al. (3) disclosed a sheet-shaped adhesive preparation comprising an adhesive layer containing certain water-soluble and water-insoluble polymers and a water-insoluble carrier which can adhere to the oral mucosa thereby releasing an active agent to the oral cavity. A number of attempts have been made to reduce the adverse feeling in the oral cavity caused by the rigidity and inflexibility of the support layer by introducing soft film supports (4-6). However, these devices still leave the patient with a considerable amount of residue from the water-insoluble support film thereby still causing a feeling of discomfort. The obvious solution to overcome this problem was to develop mucoadhesive films which completely disintegrate, or even completely dissolve in the saliva.

Invention

The present invention contemplates a rapidly dissolving film which can be adhered to the oral cavity thereby releasing a

pharmaceutically or cosmetically active agent, said film comprising water-soluble polymers, a combination of certain surfactants, one or more polyalcohols, and one or more pharmaceutically or cosmetically active ingredients. Optionally, the formulation may contain colorants, sweetening agents, flavors, flavor enhancers, or other excipients commonly used to modify the taste of formulations intended for application to the oral cavity. The resulting film is characterized by an instant wettability which causes the film to soften immediately after application to the mucosal tissue thus preventing the patient from experiencing any prolonged adverse feeling in the mouth.

The film is manufactured using conventional coating and drying techniques, cut into pieces of a shape and size that meet the requirements of the specific application, and packaged into suitable containers.

Experimental

The mucoadhesive film of the present invention contains as essential components a water-soluble polymer or a combination of water-soluble polymers, a combination of surfactants, one or more polyalcohols, and a pharmaceutically or cosmetically active ingredient. The polymers used for the mucoadhesive film include polymers which are hydrophilic and water-dispersible. The combination of surfactants used for the mucoadhesive film is a mixture of nonionic surfactants. The amount of drug to be incorporated into the film depends on the kind of drug and is usually between 0.01 and 20% (w/w). Cosmetically active agents may include breath freshening compounds like menthol, other flavors or fragrances commonly used for oral hygiene, and/or

atives used for dental and/or oral cleansing like quarternary ammonium bases. The mucoadhesive film according to the present invention can be prepared as follows: The active ingredient, surfactants, glycolalcohol, and possible other ingredients except the water-dispersible polymer are dissolved in a sufficient amount of a solvent which is compatible to them. After a clear solution has been formed, the water-dispersible polymer or mixture of water-dispersible polymers is slowly added under stirring until a clear and homogeneous solution has been formed. The solution is coated onto a suitable carrier material and dried to form a film. The carrier material must have a surface tension which allows the polymer solution to be spread evenly across the intended coating width. The coating of the solution onto the carrier material can be performed using any conventional coating equipment.

The films with desired thickness were cut or punched out for the disintegration and tensile strength tests. The tensile strength of the films was assessed using Erichsen (Model 474, A. M. Erichsen GmbH, Germany) and was expressed as the maximum force (N) (Figure 1). A 25-cm² film was placed in the petri dish which was filled with deionized water, and the time for the film to totally disintegrate was recorded (Figure 2). The decrease of integration time of formulations A to E was accompanied by the decrease of tensile force of the formulations. This correlation indicated that the choice of the most optimal formulation could be decided by using either the tensile strength or the disintegration test.

Conclusion

A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid

dissolution/disintegration upon administration in the oral cavity.

References

- (1) Sanvordeker, D.R. and Leung, S-H. S. US patent 5,047,244, 1991.
- (2) Sanvordeker, D.R. and Lenug, S-H. S. WO patent 91/06270, 1991.
- (3) Mizobuchi, T., Ohji, A., Sakoh, S. and Muguruma, Y. US Patent 4,876,092, 1989
- (4) Kuroya, T. and Inoue, Y. European Patent 0-381-194-B1, 1990.
- (5) Blank, R.G., Mody, D.S., Kenny, R.J. and Aveson, M.C. US Patent 4,946,684, 1990.
- (6) Inoue, T., Maeda, K. and Eguchi, Y. US Patent 5,206,010, 1993.




Figure 1: The tensile strength of polymer films.




Figure 2: The disintegration time of polymer films.

Water Soluble Polycations for Controlled Delivery Systems

Nandini Konar and Cherng-ju Kim


School of Pharmacy, Temple University, Philadelphia, PA 19140

Introduction

Drug delivery systems using ion exchange resins are one of the oldest processes [1]. Commercially available ion exchange resins are based on highly cross-linked poly(styrene/divinyl benzene) (sulfonated and quaternized) or cross-linked poly(methacrylic acid). Highly cross-linked gel type resins (negligible swelling) significantly sustain the release of a drug in the gel matrix, which yields \sqrt{t} release kinetics with a tailing.

Recently, swellable polyelectrolyte gel matrices have been extensively investigated as drug delivery systems. By varying the ionic pendant groups and the degree of cross-linking of the polymer chains, the degree of swelling of charged polyelectrolytes may be tailored. Several investigators used cationic and anionic hydrophobic polymers consisting of tertiary amine and methacrylic acid or acrylic acid groups, respectively, for the release of drugs [2-4]. However, due to the pH dependent swelling characteristics of charged polymers containing tertiary amine or carboxylic acid pendant groups, it was not feasible for these ionic gels to be employed as oral delivery systems, because the pH condition changes as a dosage form travels along the gastro-intestinal (GI) tract. Nujoma and Kim [5] demonstrated a (pseudo) linear release of water soluble drugs from erodible, drug/resin complex, gel tablets using noncross-linked poly(sulfopropyl methacrylate potassium *co*- methyl methacrylate) (PSPMK/MMA). Drug release from drug-PSPMK/MMA, which has a drug loading of greater than 40 wt%, maintains zero-order release kinetics for a long period of time because the drug in the matrices is bound to the polymer side chain until the complex is dissociated by incoming counter ions. It was found that drug release was independent of the pH of the dissolution medium as long as the ionic strength was higher than 0.1 M which is commonly observed in the GI fluid [6]. In addition, tablets, which are a common extended release dosage form were successfully prepared from these drug/resin complexes.

In this study, we present the zero-order release kinetics of water soluble anionic drugs from erodible, drug/polycationic, matrices (tablets) using poly(trimethylaminoethyl methacrylate chloride *co*-methacrylate) (PTMAEMC/MMA):



Experimental Methods

Synthesis of PTMAEMC/MMA and Preparation of Drug Resinate Tablets

PTMAEMC/MMA was prepared by the free-radical solution polymerization of PTMAEMC (40%) and MMA (60%) as reported earlier [7]. The polymer was dissolved in de-ionized water, and a drug solution was added to the polymer solution. The complexes precipitated in water were recovered and washed several times before being dried. The dried drug-resinates were crushed in a mortar and pestle to obtain powders. Tablets with drug-resinates and dextrose were fabricated in 9.0 mm diameter die and a flat surface punch with a Carver press.

Drug Release Kinetics Tests

The drug release kinetics from drug-resinate tablets were carried out in 0.01 M phosphate buffer containing different amounts of NaCl at 37°C by the USP basket method at 100 rpm, unless otherwise noted. Drug release was monitored on a HP8452A diode-array spectrophotometer at 250 nm and 290 nm for diclofenac Na and sulfathiazole Na as model drugs, respectively.

Results and Discussion

The effect of ionic strength on diclofenac Na release from drug-PTMAEMC/MMA complex tablets at pH 7 is shown in Figure 1. Tablets of 200mg weight were formulated with 20 % dextrose as a tablet binder. The buffer contained 0.01 M phosphate and NaCl ranging from 0.05 M to 0.2 M.